SALT LAKE CITY, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer ...

SALT LAKE CITY, June 27, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced publication of results from a large study that ...

SALT LAKE CITY, Oct. 11, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that based on recent clinical validation, its newest molecular diagnostic product, PROLARIS™, ...

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic ...

SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction ...

Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer. Myriad ...

Myriad Genetics (NASDAQ:MYGN) jumped nearly 11.5% today on news its Prolaris genetic testing method proved effective in predicting which men would see a cancer recurrence following radical prostate ...

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy 1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad ...